MCK

MCK

USD

McKesson Corporation Common Stock

$695.000+2.790 (0.403%)

Reaalajas hind

Healthcare
Medical Distribution
Ameerika Ühendriigid

Hinnagraafik

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$692.210

Kõrge

$695.630

Madal

$681.920

Maht

0.11M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

87.1B

Tööstusharu

Medical Distribution

Riik

United States

Kauplemisstatistika

Keskmine maht

0.99M

Börs

NYQ

Valuuta

USD

52 nädala vahemik

Madal $464.42Praegune $695.000Kõrge $728.32

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 25. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

MCK: McKesson Corporation Common Stock - Analyzing Recent Moves & What Might Come Next

Stock Symbol: MCK Generate Date: 2025-04-25 23:30:15

Let's break down what's been happening with McKesson stock lately, looking at the news, how the price has moved, and what some predictions are saying.

Recent News Buzz

The news flow around MCK has been mostly positive lately, especially from the folks who analyze stocks professionally. We saw a few big names – B of A Securities, Mizuho, and Morgan Stanley – all come out and say they like the stock. Not only did they keep their positive ratings (like "Buy" or "Overweight"), but they also bumped up the price they think the stock is worth in the future. B of A, for instance, raised their target price quite a bit, from $665 all the way up to $755. Morgan Stanley and Mizuho also lifted their targets, though not quite as dramatically.

So, the main vibe from the analyst community is definitely upbeat. They seem to think McKesson has more room to grow.

There was also news about Rite Aid potentially filing for bankruptcy again. Now, McKesson is a major drug distributor, and Rite Aid is a customer. This kind of news is something to keep an eye on because a customer having financial trouble could potentially impact a supplier like McKesson. However, the analyst upgrades came out after or around the same time as the Rite Aid news, and they were still positive. This suggests that, based on the information provided, the market might be focusing more on McKesson's overall strength or other business areas rather than seeing the Rite Aid situation as a major immediate threat to MCK's outlook. The dominant news signal here is clearly the analyst confidence.

Checking the Price Action

Looking at the stock chart over the past few months, MCK has been on a pretty solid upward trend. It started the year trading in the high $500s and low $600s. Fast forward to April, and we saw a significant jump, with the price hitting a peak around $728 early in the month. Since that spike, the stock has pulled back a bit and has been trading mostly sideways, hovering in the high $600s. The last reported price is $695.00.

So, the stock has made a big move up, and now it seems to be consolidating or taking a breather around this higher level.

What about the future? An AI model that looks at stock prices is predicting a slight upward movement over the next couple of days. It sees the price potentially moving up by a few percent. This aligns somewhat with the recent trend of holding onto gains after the big April jump.

Putting It All Together: Outlook & Ideas

Based on the analyst optimism, the stock's recent strong upward move (even with the recent pause), and the AI's short-term positive prediction, the situation for MCK looks generally favorable right now. The analysts raising their price targets tells us they believe the stock is undervalued even at these higher levels. The price chart confirms the stock has been strong, and the AI suggests that strength might continue in the very near term.

Given this picture, the apparent near-term leaning seems to favor potential buyers or those already holding the stock. It looks like there might be room for the price to climb further, especially if it can break out of this recent sideways trading range.

If someone were considering getting into this stock, the current price area around $695 could be a point to watch. It's right where the stock has been trading recently, and the AI prediction suggests it could move up from here. The recommendation data also pointed to potential entry points slightly below the current price, which could be interesting if the stock dips a little.

For managing risk, thinking about potential exit points is smart. If the stock continues its upward path, the recent high near $728 could be a level where some investors might consider taking some profits. The higher analyst targets, like $745 or $755, represent more optimistic views of where the stock could go over a longer period. On the downside, setting a stop-loss order is crucial to limit potential losses. The recommendation data suggested a stop-loss around $619.21. While that's quite a bit below the current price, it's a level that, if broken, might signal a significant change in the stock's trend. A tighter stop might also be considered depending on an individual's risk tolerance and investment horizon.

Company Context

It's helpful to remember that McKesson is a giant in the healthcare sector, primarily focused on medical distribution. They move drugs and supplies to pharmacies, hospitals, and other healthcare providers. This business model means they are deeply connected to the healthcare system's overall health and the dynamics of drug pricing and distribution. That's why news about pharmacies (like Rite Aid) or analyst views on the healthcare supply chain are particularly relevant to MCK's performance.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Seotud uudised

Analyst Upgrades

B of A Securities Maintains Buy on McKesson, Raises Price Target to $755

B of A Securities analyst Michael Cherny maintains McKesson with a Buy and raises the price target from $665 to $755.

Vaata rohkem
B of A Securities Maintains Buy on McKesson, Raises Price Target to $755
Reuters

Rite Aid weighs repeat bankruptcy filing, WSJ reports

U.S. pharmacy chain Rite Aid is weighing a possible repeat bankruptcy after its recent financial restructuring failed to put the drugstore chain on a sustainable path, the Wall Street Journal reported on Friday.

Vaata rohkem
Rite Aid weighs repeat bankruptcy filing, WSJ reports
Analyst Upgrades

Mizuho Maintains Neutral on McKesson, Raises Price Target to $690

Mizuho analyst Steven Valiquette maintains McKesson with a Neutral and raises the price target from $630 to $690.

Vaata rohkem
Mizuho Maintains Neutral on McKesson, Raises Price Target to $690
Analyst Upgrades

Morgan Stanley Maintains Overweight on McKesson, Raises Price Target to $745

Morgan Stanley analyst Erin Wright maintains McKesson with a Overweight and raises the price target from $642 to $745.

Vaata rohkem
Morgan Stanley Maintains Overweight on McKesson, Raises Price Target to $745

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 27. apr 2025, 22:34

LangevNeutraalneTõusev

69.6% Kindlus

Risk ja kauplemine

Riskitase1/5
Madal risk
Sobib
Konservatiivne
Kauplemisjuhend

Sisenemispunkt

$695.41

Võta kasum

$733.16

Peata kahjum

$625.31

Põhitegurid

PDI 5.8 on MDI 3.8 kohal ADX-iga 18.1, mis viitab tõusutrendile
Praegune hind on tugitasemele ($693.19) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 5.8x keskmisest (11,244), mis viitab äärmiselt tugevale ostusurvele
MACD 0.5998 on signaalijoone 0.6557 all, mis viitab langevale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.